Skip to content

Quality Control of CE-Certified Phonak Hearing Aids - 2018_07

Quality Control of CE-Certified Phonak Hearing Aids - 2018_07

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03555084
Enrollment
16
Registered
2018-06-13
Start date
2018-05-22
Completion date
2018-06-22
Last updated
2018-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hearing Loss, Sensorineural

Brief summary

Phonak Hearing Systems pass through different development and study stages. At an early stage, feasibility studies are conducted to investigate new algorithms, features and functions in an isolated manner. If the benefit is proven, their performance is then investigated regarding interdependency between all available algorithms, features and functions running in parallel in a hearing aid (pivotal/pre-validation studies) and, as a result, they get optimized. Afterwards, and prior to product launch, the Phonak Hearing Systems undergo a final quality control in terms of clinical trials. This is a pre-validation study, investigating optimized algorithms, features, functions and wearing comfort. This will be a clinical evaluation which will be conducted mono centric at Sonova AG Headquarters based in Stäfa (Switzerland).

Interventions

DEVICEExtension of Virto B-Titanium

In ear Hearing aid device individually modeled to ear canal geometry to compensate an individual Hearing loss.

DEVICEVirto B-Titanium

In ear Hearing aid device individually modeled to ear canal geometry to compensate an individual Hearing loss.

Sponsors

Sonova AG
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult hearing impaired persons (minimum age: 18 years) with or without experience with hearing aids * Good written and spoken (Swiss) German language skills * Healthy outer ear * Ability to fill in a questionnaire (p/eCRF) conscientiously * willingness to wear custom made Hearing aids * Informed Consent as documented by signature * Benefit with TFG tool at least on one ear

Exclusion criteria

* Contraindications to the MD in this study, e.g. known hypersensitivity or allergy to the investigational product * Limited mobility and not in the position to attend weekly appointments in Stäfa (Switzerland) * Limited ability to describe listening impressions/experiences and the use of the hearing aid * Inability to produce a reliable hearing test result * Limited dexterity (not able to change a 10size Hearing aid battery) * no Benefit of the TFG tool on both ears * Known psychological problems * Central hearing disorders

Design outcomes

Primary

MeasureTime frameDescription
Visibility and Wearing Comfort3 weeksThe primary objective of this study is to evaluate if Virto B-Titanium hearing aids measured with the Titanium FitGuide (TFG) (extension of Virto B-Titanium) are less visible (deeper) than modeling without TFG (Virto B-Titanium) while maintaining wearing comfort on adult participants (new and existing users) with mild to moderately-severe hearing loss (M and P receiver ).

Secondary

MeasureTime frameDescription
Measurement of acoustic Feedback Thresholds3 weeksSecondary objective is to compare the acoustic feedback thresholds of the TFG- and without TFG- modeled devices in regard of an adequate sealing effect of the respective devices. Thereby, feedback thresholds, measured with the Phonak Target fitting software, must be comparable to average feedback threshold values of the respective shell forms (IIC / CIC). Acceptable feedback thresholds must guarantee an insertion gain \[in dB SPL\] of at least 20 dB in a specific frequency range.

Other

MeasureTime frameDescription
TFG Fitrate3 weeksAnother objective is to investigate whether at least 50% of the screened population will get a deeper fitted device by the use of the TFG tool, proven by modelling software

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026